EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 453 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research July 13, 2020 ‘From virtual reality tumours to cutting-edge treatments’: what to expect from... May 23, 2022 What to Know About Cancer Care and Research for People 65+:... February 28, 2023 Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia June 5, 2018 Load more HOT NEWS Structured Exercise Programme Initiated Soon After the Completion of Adjuvant Chemotherapy... Greater OS Benefit Among Patients with Advanced Cancer Treated with Matched... Facing Crisis After Crisis During Cancer: How to Cope Fisioterapeutas en oncología
